**Core tip:** Previous studies have shown that colonoscopies performed with Entonox^®^ gas are not associated with more patient discomfort, or lower caecal intubation rates, than those performed with intravenous conscious sedation. We have completed the largest and most comprehensive real-world retrospective study of Entonox use in colonoscopy. In particular, we compare colonoscopy quality with Entonox against intravenous conscious sedation using midazolam plus opioid. This study shows that Entonox is not associated with lower colonoscopy quality when compared to intravenous conscious sedation. Based on the results of this study, Entonox remains an attractive option for colonoscopy analgesia and sedation.

INTRODUCTION
============

Nitrous oxide gas (N~2~O) has well established analgesic and sedative properties\[[@B1]-[@B4]\]. It is likely that the analgesic effect of nitrous oxide is opioid receptor-mediated\[[@B5],[@B6]\]. Furthermore, and although less well characterised, animal models suggest that the anxiolytic effect of nitrous oxide is benzodiazepine receptor-mediated\[[@B7]\].

Entonox^®^ (50% nitrous oxide: 50% oxygen) is routinely used as a patient-controlled inhaled analgesic and sedative. In particular, it is used in various emergency, orthopaedic, and obstetric procedures\[[@B8],[@B9]\]. It is not as frequently used in gastrointestinal (GI) endoscopy, with intravenous conscious sedation (benzodiazepine use in combination with an opioid) being the standard sedation regime in the United Kingdom\[[@B10]\].

A useful way of examining standards in colonoscopy practice is to use the framework of "colonoscopy quality\[[@B11]-[@B13]\]. The aim of current colonoscopy quality guidelines \[jointly adopted by the Joint Advisory Group on GI Endoscopy, the British Society of Gastroenterology (BSG), and the Association of Coloproctology of Great Britain and Ireland\] is to improve patient care\[[@B14]\]. Three important markers of colonoscopy quality are: (1) \< 10% of patients should experience moderate or severe discomfort; (2) the caecal intubation rate (CIR) should be ≥ 90%; and (3) the polyp detection rate (PDR) should be ≥ 15%\[[@B14]\].

Welchman et al\[[@B15]\] conducted a systematic review of Entonox use in colonoscopy. Their review, which included a total of 623 patients, was based on data from 9 small randomised controlled trials (RCTs). The authors concluded that "N~2~O provides comparable analgesia to *i.v*. sedation". A Cochrane review of 547 patients (from 7 of the RCTs), where the primary outcome was adequate pain relief during the procedure, similarly, reached the conclusion that Entonox was "as efficient" as intravenous sedation in reducing pain/discomfort during colonoscopy\[[@B16]\].

Neither the Welchman et al\[[@B15]\] and Aboumarzouk et al\[[@B16]\] nor Cochrane reviews found (based on more limited data) any difference in CIRs when Entonox and intravenous sedation groups were compared directly. However, CIRs were found, in a large prospective study by Radaelli et al\[[@B17]\], to be higher in the intravenous benzodiazepine (*n* = 3701; CIR = 83.1%) *vs* unsedated (*n* = 5737; CIR = 76.1%) groups (OR = 1.460, 95%CI: 1.282-1.663). Radaelli et al\[[@B17]\] also demonstrated that PDRs were higher in intravenous benzodiazepine (*n* = 3701; PDR = 26.9%) *vs* unsedated (*n* = 5737; PDR = 26.5%) groups (OR = 1.121, 95%CI: 1.016-1.236). A small study at a UK private hospital found a higher adenoma detection rate (but not PDR) in the Entonox group compared to the intravenous sedation group\[[@B18]\].

Endoscopic procedure data from UK endoscopy units have been used to retrospectively analyse colonoscopy quality associated with different types of analgesia/sedation. Two independently conducted retrospective studies of NHS endoscopy units (one of 2873 patients at Altnagelvin Area Hospital, Northern Ireland\[[@B19]\] and another of 322 patients at Furness General Hospital, England\[[@B20]\]) have found that CIRs, PDRs, and patient comfort scores were similar in patients receiving Entonox *vs* intravenous sedation.

In this study we assessed the quality of colonoscopies performed with Entonox against intravenous conscious sedation (abbreviated in this article as IVM) using intravenous midazolam plus opioid. We also compared colonoscopy quality with an unmedicated group against IVM. We used the following markers of colonoscopy quality: (1) patient comfort scores; (2) CIRs; and (3) PDRs.

MATERIALS AND METHODS
=====================

Study design and setting
------------------------

Eighteen thousand six hundred and eight colonoscopies were undertaken between July 2013 and January 2016 at one of four NHS colonoscopy units within Lothian health board: (1) the Royal Infirmary of Edinburgh; (2) the Western General Hospital, Edinburgh; (3) St John's Hospital, Livingston; or (4) Roodlands Hospital, Haddington. Relevant patient and procedural data was recorded by the endoscopist/nurse at the time of colonoscopy using Unisoft's electronic GI Reporting Tool (Unisoft Medical Systems, Enfield, United Kingdom). The database was retrospectively analysed.

Procedures were performed using Olympus XQ 240 and XQ260 and Fuji EC530WL and EC600WL colonoscopes. Generally during the procedures the endoscopist and two nurses where present, regardless of regime type, and patients routinely had blood pressure, heart rate and oxygen saturation monitoring.

At each of these units, throughout this timeframe, patients were offered the choice of either: (1) Entonox; (2) intravenous conscious sedation (IVM) with midazolam plus or minus opioid; or (3) no sedation or analgesia (*i.e*., unmedicated), each administered by the performing endoscopist. Patients offered Entonox had the option of fentanyl plus or minus midazolam as an adjunct if required and clinically appropriate. There were 234 individual cases of patients receiving both Entonox and midazolam sedation (1.26% of the total), and all these cases were all excluded from the analysis. This situation could have arisen in the case where the patient was not adequately responding to IVM and Entonox was then introduced as an adjunct or vice versa. Ninety-nine percent of patients receiving IVM had a combination of fentanyl analgesia and midazolam sedation at the start of the procedure.

Local exclusion criteria for Entonox
------------------------------------

Local exclusion criteria for the use of Entonox are head injury or altered GCS, maxillo-facial injuries, drug or alcohol intoxication, pneumothorax or chest trauma, decompensated respiratory disease, decompression sickness or recent underwater diving, the first sixteen weeks of pregnancy, middle ear occlusion, high risk infection, *e.g*., MRSA/VRE or vitamin B12 deficiency (see the regulator-approved summary of product characteristics\[[@B21]\]).

Measured variables
------------------

A "polyp" was defined as such by the performing endoscopist when reporting the investigation. For the purpose of this study polyps were either detected or not detected. Caecal intubation was confirmed by identification of caecal landmarks and recording these in the reporting software with supporting photo-documentation where possible. For the purpose of this study caecal intubation was either achieved or was not achieved.

Patient comfort score was endoscopist/nurse reported and recorded as either: "no discomfort", "mild discomfort", "moderate discomfort", "severe discomfort", or "extreme discomfort".

In the primary analysis "moderate", "severe", and "extreme" discomfort were combined into a single "moderate-to-extreme" discomfort binary variable because this was felt to be the most clinically relevant approach and is consistent with the current United Kingdom colonoscopy quality guidelines\[[@B14]\]. A secondary analysis compared rates of mild discomfort between sedation groups. This analysis only included the subgroup of patients that had either "no" or "mild" discomfort, *i.e*., patients with either "moderate, "severe", and "extreme" discomfort were excluded from the analysis. Therefore, in this secondary analysis, the new patient comfort variable was again a binary variable.

Statistical analysis
--------------------

The data were exported from the Unisoft GI reporting tool to an Excel 2016 spreadsheet (Microsoft Corporation, WA, United States). The statistical analysis was subsequently performed by importing the data into the software package R Version 3.2.3 (R Foundation for Statistical Computing, Vienna, Austria). The caecal intubation and polyp detection variables were separately analysed using binary logistic regression to assess for an association with different types of colonoscopy analgesia/sedation. The caecal intubation and polyp detection fields were treated as binary dependent variables. Patient age and gender were included as independent variables.

RESULTS
=======

Patient characteristics and analgesia/sedation regimes
------------------------------------------------------

One thousand five hundred and one colonoscopies were excluded for one or more of 5 reasons: (1) the patient was a child under the age of 18 (*n* = 35); (2) the comfort score was not recorded (*n* = 154); (3) the patient had undergone a general anaesthetic (*n* = 26); (4) the patient was administered both Entonox and midazolam (*n* = 234); and (5) the patient had opioid alone (*n* = 1091). This left a total of 17107 patients to be included in the final analysis (Table [1](#T1){ref-type="table"}).

###### 

Descriptive statistics of demographic and medication variables for patients receiving different analgesia/sedation regimes

  **Variable**                            **Type of analgesia/sedation**                       
  --------------------------------------- -------------------------------- ------------------- ------------------
  Gender                                                                                       
  Female (% of females)                   6753 (76.0%)                     1609 (18.1%)        520 (5.9%)
  Male (% of males)                       4613 (56.1%)                     2239 (27.2%)        1373 (16.7%)
  Median age/yr (IQR)                     61.1 (50.7-70.1)                 60.4 (50.8-69.1)    63.8 (54.3-71.4)
  Median midazolam dose/mg (IQR)          2.5 (2.0-3.0)                                        
  Opioid, mcg                                                                                  
  Number (%) given fentanyl               10255 (90.2%)                    258 (6.7%)          0 (0.0%)
  Number (%) given pethidine              1060 (9.3%)                      27 (0.7%)           0 (0.0%)
  Total number (%) given an opioid        11299 (99.4%)                    284 (7.4%)          0 (0.0%)
  Median fentanyl equivalent dose (IQR)   75.0 (50.0-100.0)                75.0 (50.0-100.0)   

IQR: Interquartile range.

Patient comfort score
---------------------

A graphical representation of comfort scores by analgesia/sedation type and gender is shown in Figure [1](#F1){ref-type="fig"}. There was no difference in the rate of moderate-to-extreme discomfort in the Entonox group compared to the IVM group (17.9% *vs* 18.8%; OR = 1.06, 95%CI: 0.95-1.18, *P* = 0.27) (Table [2](#T2){ref-type="table"}). Patients in the unmedicated group were less likely to experience moderate-to-extreme discomfort than those in the IVM group (11.4% *vs* 18.8%; OR = 0.71, 95%CI: 0.60-0.83, *P* \< 0.001).

![Patient comfort scores by sedation type used and patient gender. This figure uses 100% stacked bars to provide a graphical representation of the proportions of each level of patient discomfort (see legend; inset right) with each sedation type in females (A) and males (B).](WJGE-9-471-g001){#F1}

###### 

Moderate-to-extreme against none-mild discomfort by analgesia/sedation type

  **Variable[1](#T2FN1){ref-type="table-fn"}**   **No. with moderate-to-extreme discomfort (%)[2](#T2FN2){ref-type="table-fn"}**   **Odds ratio (95%CI)[1](#T2FN1){ref-type="table-fn"}**   ***P* value[1](#T2FN1){ref-type="table-fn"}**
  ---------------------------------------------- --------------------------------------------------------------------------------- -------------------------------------------------------- -----------------------------------------------
  Sedation type                                                                                                                                                                             
  Midazolam ± opioid                             2137 (18.8)                                                                       Reference                                                
  Entonox ± opioid                               689 (17.9)                                                                        1.06 (0.95-1.18)                                         0.27
  Unmedicated                                    215 (11.4)                                                                        0.71 (0.60-0.83)                                         \< 0.001
  Age                                                                                                                              1.00 (1.00-1.01)                                         0.08
  Gender                                                                                                                                                                                    
  Female                                         2114 (23.9)                                                                       Reference                                                
  Male                                           927 (11.3)                                                                        0.40 (0.36-0.43)                                         \< 0.001

The dichotomous "moderate-to-extreme"/"none-mild" discomfort dependent variable was regressed on the sedation type, age, and gender independent variables using binary logistic regression. Output is expressed as odds ratios and *P* values;

This column lists the number (simple percentage) of patients with moderate-to-extreme discomfort in each sedation type and gender group.

There was no statistical association of age with moderate-to-extreme discomfort (OR = 1.00, 95%CI: 1.00-1.01, *P* = 0.08). Males were less likely to experience moderate-to-extreme discomfort than females (11.3% *vs* 23.9%; OR = 0.40, 95%CI: 0.36-0.43, *P* \< 0.001).

Amongst only those patients experiencing mild or no discomfort, Entonox was associated with greater likelihood of mild discomfort compared to IVM (64.7% *vs* 58.9%; OR = 1.46, 95%CI: 1.33-1.61, *P* \< 0.001).

Caecal intubation
-----------------

In addition to the exclusions listed at the beginning of this section, 74 cases where the extent of intubation was listed as "anastomosis" were excluded from the caecal intubation calculation. A further 3 cases where the extent of intubation was not recorded were also excluded.

There was no difference in caecal intubation between the Entonox and IVM groups (94.4% *vs* 93.7%; OR = 1.08, 95%CI: 0.92-1.28, *P* = 0.34) (Table [3](#T3){ref-type="table"}). Furthermore, there was no difference in caecal intubation between the unmedicated and IVM groups (94.2% *vs* 93.7%; OR = 0.98, 95%CI: 0.79-1.22, *P* = 0.87).

###### 

Caecal intubation for patients receiving different analgesia/sedation regimes

  **Variable[1](#T3FN1){ref-type="table-fn"}**   **Caecal intubation rate, *n* (%)[2](#T3FN2){ref-type="table-fn"}**   **Odds ratio (95%CI)[1](#T3FN1){ref-type="table-fn"}**   ***P* value[1](#T3FN1){ref-type="table-fn"}**
  ---------------------------------------------- --------------------------------------------------------------------- -------------------------------------------------------- -----------------------------------------------
  Sedation type                                                                                                                                                                 
  Midazolam ± opioid                             10562 (93.7)                                                          Reference                                                
  Entonox ± opioid                               3612 (94.4)                                                           1.08 (0.92-1.28)                                         0.34
  Unmedicated                                    1763 (94.2)                                                           0.98 (0.79-1.22)                                         0.87
  Age                                                                                                                  0.98 (0.97-0.98)                                         \< 0.001
  Gender                                                                                                                                                                        
  Female                                         8159 (92.7)                                                           Reference                                                
  Male                                           7778 (95.3)                                                           1.61 (1.41-1.85)                                         \< 0.001

The dichotomous caecal intubation dependent variable was regressed on the sedation type, age, and gender independent variables using binary logistic regression. Output is expressed as odds ratios and *P* values.

This column lists the number (simple percentage) of patients in which caecal intubation was achieved in each sedation type and gender group.

There was a negative association of age with caecal intubation (OR = 0.98, 95%CI: 0.97-0.98, *P* \< 0.001). Males had higher caecal intubation compared to females (95.3% *vs* 92.7%; OR = 1.61, 95%CI: 1.41-1.85, *P* \< 0.001).

PDR
---

Polyp detection in the Entonox group was not significantly different from the IVM group (35.0% *vs* 33.1%; OR = 1.01, 95%CI: 0.93-1.10, *P* = 0.79) (Table [4](#T4){ref-type="table"}). Furthermore, polyp detection in the unmedicated group was not significantly different from the IVM group (37.4% *vs* 33.1%; OR = 0.97, 95%CI: 0.87-1.08, *P* = 0.60).

###### 

Polyp detection for patients receiving different analgesia/sedation regimes

  **Variable[1](#T4FN1){ref-type="table-fn"}**   **Polyp detection rate, *n* (%)**   **Odds ratio (95%CI)[1](#T4FN1){ref-type="table-fn"}**   ***P* value[1](#T4FN1){ref-type="table-fn"}**
  ---------------------------------------------- ----------------------------------- -------------------------------------------------------- -----------------------------------------------
  Sedation type                                                                                                                               
  Midazolam ± opioid                             3755 (33.1)                         Reference                                                
  Entonox ± opioid                               1345 (35.0)                         1.01 (0.93-1.10)                                         0.79
  Unmedicated                                    707 (37.4)                          0.97 (0.87-1.08)                                         0.6
  Age                                                                                1.03 (1.03-1.03)                                         \< 0.001
  Gender                                                                                                                                      
  Female                                         2454 (27.7)                         Reference                                                
  Male                                           3353 (40.8)                         1.83 (1.71-1.96)                                         \< 0.001

The dichotomous polyp detection dependent variable was regressed on the sedation type, age, and gender independent variables using binary logistic regression. Output is expressed as odds ratios and *P* values. 2This column lists the number (simple percentage) of patients in which polyp(s) was/were detected in each sedation type and gender group.

There was a positive association of age with polyp detection (OR = 1.03, 95%CI: 1.03-1.03, *P* \< 0.001). Males had higher polyp detection compared to females (40.8% *vs* 27.7%; OR = 1.83, 95%CI: 1.71-1.96, *P* \< 0.001).

DISCUSSION
==========

Previous systematic reviews of the clinical trial data, although limited by the small sample sizes of the constituent trials, show nitrous oxide to be as effective as IVM in controlling patient discomfort during colonoscopy. Furthermore, they show that CIRs are comparable between the two groups\[[@B15],[@B16]\]. The two independently conducted retrospective studies of real-world colonoscopy data have also suggested equivalence between nitrous oxide and IVM. However, in addition to their relatively small sample size, these latter studies were notably limited by the way in which they analysed the data using descriptive and basic inferential statistics\[[@B19],[@B20]\]. There has therefore been a need for a larger and more comprehensive retrospective study.

In our study we used binary logistic regression to model the data. We found no difference in moderate-to-extreme discomfort experienced, caecal intubation, and polyp detection between the intravenous medication and Entonox groups.

Our study therefore supports and strengthens the data from existing studies in suggesting that using Entonox is not associated with lower colonoscopy quality than IVM.

The key implication of this finding is that patients can continue to be offered the same level of choice with respect to their colonoscopy analgesia/sedation. There are many factors associated with Entonox use that may be attractive to patients relative to IVM. For example, some patients are likely to be attracted by the rapid post-procedure recovery associated with Entonox use\[[@B15],[@B16]\]. In particular, after using Entonox patients have the potential to be discharged after just 30 min\[[@B22]\], are safe to drive\[[@B23]\], and do not require overnight home supervision by a responsible person. This could manifest itself in improved patient satisfaction levels with their post-procedural care. Furthermore, although outside the remit of this study, it could contribute to efficiency and cost savings in the endoscopy department by optimising patient flow.

As measured by CIR and PDR the overall quality of colonoscopy performed in the included centres was good. All groups met the ≥ 90% (CIR) and ≥ 15% (PDR) BSG/Joint Advisory Group on GI Endoscopy/Association of Coloproctology standards\[[@B14]\]. Furthermore we were gratified, because of its implication of good colonoscopy technique, to see that the unmedicated group experienced a lower level of discomfort compared to the IVM group. We are not aware of any previous studies demonstrating an association of no sedation with lower levels of patient discomfort. Ristikankare et al\[[@B24]\] found no significant difference in patient experience between an intravenous midazolam sedation group and a no intravenous cannula control group. Furthermore, studies have demonstrated the feasibility of unsedated colonoscopy\[[@B25],[@B26]\]. The NordICC study is a large population-based RCT into the effectiveness of colonoscopy screening for colorectal cancer. The NordICC study group has published an interim data analysis showing that overall "pain during colonoscopy was not significantly associated with the use of sedation (adjusted odds ratio, 0.91; 95%CI: 0.61-1.35)"\[[@B27]\].

Within this analysis the CIR and PDR of the unmedicated group where not significantly different compared with the IVM patients.

Polyp detection rate was used rather than adenoma detection as analysis was based on reports written during and immediately following the procedure, and as such prior to histological differentiation of the polyp.

The way that Entonox is used by GI endoscopists in the UK varies. In particular, some endoscopists use Entonox as a primary agent, whereas others use it as an adjunct to another standard analgesia/sedation regime. Within Lothian health board Entonox is principally used as a primary agent. In only 234 cases, 1.26% of the total number, were patients administered both Entonox and intravenous midazolam. Consequently, variability in Entonox use with respect to its primary or adjunctive status was not something that could be addressed by this study.

The introduction of comfort scores in the assessment of colonoscopy quality was initially recommended by the BSG Endoscopy Committee in order to monitor whether, in striving to achieve total colonoscopy to the caecum, endoscopists were causing unacceptable pain and distress to patients\[[@B13],[@B28]\]. However, it has been demonstrated that the best colonoscopists (typically those performing the most procedures per annum) have "a higher CIR, use less sedation, cause less discomfort and find more polyps"\[[@B28]\]. This highlights the importance of the technical skill of the endoscopist in relation to patient comfort during colonoscopy. Indeed, the initial data from the NordICC study show that individual endoscopist performance is associated with significant variability in CIRs, adenoma detection rates, and the percentage of participants with moderate or severe pain\[[@B27]\].

Interestingly, among the subgroup of patients experiencing "none" or "mild" discomfort, Entonox was associated with more patients having "mild" discomfort when compared to IVM. This was a secondary analysis, as it was felt that (in line with the UK guidelines and the ongoing NordICC study) patient discomfort is most important when it is moderate or worse\[[@B14],[@B27]\]. Furthermore, there have been differences reported in the way that nurses, endoscopists, and patients report comfort. In particular, Rafferty et al\[[@B29]\] found that nurses tend to give higher comfort scores, in other words report more discomfort, than the endoscopist and the patient. This suggests that the distinction between "none" and "mild" discomfort is potentially not meaningful. Furthermore, the use of the Entonox apparatus during colonoscopy is likely to be associated with a learning curve, with colonoscopy technique modification required to maximise its effect. As such there is likely to be inter-operator variability in outcomes with Entonox. Within this study there was no data collected on the individual endoscopists experience in relation to patient outcomes but further discussion and study into the importance of the endoscopist with respect to Entonox would be highly beneficial.

There was a marked gender effect in our patient population. Females experienced significantly worse patient comfort scores, CIRs, and PDRs. Indeed, these gender differences in comfort scores\[[@B27],[@B30]-[@B32]\], caecal intubation rates or times\[[@B33],[@B34]\], and PDRs/adenoma detection rates\[[@B35],[@B36]\] are well established in the literature. The difference with respect to comfort scores can potentially be accounted for by two physical factors. Firstly, females have a pelvic anatomy, and a longer colon that are more predisposed to "looping" than in males\[[@B37],[@B38]\]. Secondly, gynaecological surgery can result in anatomical distortion and pelvic or abdominal adhesions that make colonoscopy more difficult, and therefore more uncomfortable for the patient. This is supported by the evidence that previous hysterectomy is associated with greater discomfort during colonoscopy\[[@B31],[@B39],[@B40]\]. It has been postulated that responses to pain and discomfort may be related to psychosocial factors\[[@B41]\]. However, we are not aware of any study that has sufficiently differentiated these factors from past surgical history and other considerations. Within our analysis procedures with the limit listed as "anastomosis" have been removed. As further surgeries have been incompletely documented they have not been corrected for. Overall, the uncertainty of the relative importance of these factors highlights the need for future clinical research in colonoscopy analgesia and sedation to consider the possibility of important gender differences generally, as well as more specifically in relation to response to sedation.

There was the potential in this study for patient and endoscopist selection bias. This might explain the observation that unmedicated patients experienced lower levels of discomfort when compared to the IVM group. Patients who had previous high tolerance of colonoscopy for example would be likely to select the unmedicated option. Endoscopist and nurse reporting of comfort scores may also have significant inter-observer variability. Furthermore, patient comfort scores were entirely endoscopist or nurse reported. There was no data recorded on analgesics being taken regularly prior to the procedure or whether the recorded procedure was their first.

Although data was collected on the indications for colonoscopy these were similar between the groups and as such not included in the final analysis.

Procedures were carried out by a combination of gastroenterologists, surgeons and nurse endoscopists with varying experience. This information, and the personal experience of the endoscopist was not included within this study.

Bowel preparation, its quality, colonoscopy technique and complication rates were not included within the data analysed. Within the endoscopy departments a Moviprep based schedule was most commonly used. The predominant technique employed was air insufflations although carbon dioxide insufflation was also common and exceptions to this are likely to be equally distributed among the groups.

This is a large retrospective study whose merits lie not in the systematic elimination of bias but rather in observing the real-world quality markers associated with the different analgesia and sedation regimes. This type of study is therefore important for its ability to encourage and facilitate quality and service improvement.

In conclusion, this study shows that Entonox is not associated with lower colonoscopy quality when compared to intravenous conscious sedation. Entonox therefore remains an attractive option for colonoscopy analgesia and sedation. In most cases, decisions regarding analgesia and sedation are the result of an informed discussion between patient and endoscopist in which several factors, such as patient comorbidities and individual patient preferences, are taken into account.
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